CellMed

JBKLAB said it has signed an exclusive sales contract with Belgium's Tilman for its venous circulation improvement drug "Vinofytol," which is effective in improving symptoms of venous failure such as venous edema, night leg cramps, and leg pain.

The main ingredient of the venous circulation ameliorating agent Veinofytol, which was signed this time, is a natural plant-active substance called Aescin, which is contained in the extract of western ciliate seeds. It is a substance that has clinical effects on various symptoms caused by venous insufficiency that occurs frequently in modern people.

With more than 65 years of history, Tilman is one of the largest pharmaceutical companies in Belgium. It develops over-the-counter medicines and health supplements using natural plant ingredients with proven clinical efficacy, and sells them in more than 30 countries around the world and in Europe. A Cellmed official said, "Tilman has a number of products with various natural ingredients that meet the value added by Cellmed as well as Veinofytol. We will introduce Tilman's products to the Korean market sequentially, starting with Veinofytol, and deliver products with excellent clinical effect and excellent safety to Korean patients."

Dr. Jang Bong-geun, CEO of JBKLAB, said, "We are very happy to sign an exclusive sales partnership with Tillman for Veinofytol, a clinically proven intravenous circulation improvement drug with natural plant active ingredients," adding, "We will continue to introduce promising over-the-counter drugs from abroad, and at the same time, we will find and deliver various products that combine Selmed's medicine technology and product development know-how to pharmacists and customers the fastest way."

Meanwhile, Jean-Noël Tillman, president of Tilman in Belgium, said, "Our partnership with JBKLAB, which has established itself as a game changer in the Korean pharmacy market, is expected to be of great help to Tilman's global growth. Through JBKLAB, we also want to introduce products with various natural ingredients that Tilman has to Korean consumers."

JBKLAB, which was reborn as a pharmaceutical company through the absorption and merger of JBK Pharmaceutical, released its first product, Acoxpene Ribosan, in July, and supplies over-the-counter medicines to consumers through Cellmed's full-time pharmacy. JBKLAB will release several herbal products sequentially that incorporate Cellmed's medicine technology, while continuously introducing excellent over-the-counter drugs from abroad.